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ABSTRACT
Tamoxifen (TAM) remains the adjuvant therapy of choice for pre-menopausal 
women with ERα-positive breast cancer. Resistance and recurrence remain, however, 
a major challenge with many women relapsing and subsequently dying. The insulin-
like growth factor (IGF) axis is involved in breast cancer pathogenesis and progression 
to endocrine resistant disease, but there is very little data on the expression and 
potential role of IGF-binding proteins (IGFBP) during acquisition of the resistant 
phenotype. The aim of this study was to determine the expression and functional role 
of IGFBP-2 and -5 in the development of TAM resistance (TamR) in vitro and to test 
retrospectively whether they were predictive of resistance in a tissue microarray of 77 
women with primary breast cancers who relapsed on/after endocrine therapy and 193 
who did not with long term follow up. Reciprocal expression of IGFBP-2 and IGFBP-5 
was observed at both mRNA and protein level in TamR cells. IGFBP-2 expression was 
increased by 10-fold while IGFBP-5 was decreased by 100-fold, compared to TAM-
sensitive control cells. shRNA-mediated silencing of IGFBP-2 in TamR cells restored 
TAM sensitivity suggesting a causal role for this gene in TamR. While silencing of 
IGFBP-5 in control cells had no effect on TAM sensitivity, it significantly increased the 
migratory capacity of these cells. Quantitative image analysis of immunohistochemical 
data failed, however, to demonstrate an effect of IGFBP2 expression in endocrine-
relapsed patients. Likewise, IGFBP-2 and IGFBP-5 expression failed to show any 
significant associations with survival either in patients relapsing or those not relapsing 
on/after endocrine therapy. By contrast, in silico mining of a separate published 
dataset showed that in patients who received endocrine treatment, loss of expression 
of IGBP-5 was significantly associated with worse survival. Overall these data suggest 
that co-ordinated and reciprocal alteration in IGFBP-2 and –5 expression may play a 
role in the acquisition of endocrine resistance.
INTRODUCTION
Development of resistance to anti-oestrogen therapies 
in patients with ER+ breast cancer (BC) represents a major 
therapeutic challenge. This is particularly evident in the 
eventual failure of adjuvant tamoxifen in a proportion 
of patients, particularly in the premenopausal setting 
where it remains the therapy of choice. Although there is 
growing evidence that other signalling pathways provide 
an alternative mitogenic drive to epithelial tumour cells 
resistant to tamoxifen [1], the precise molecular detail 
of such mechanisms remains unclear. The insulin-like 
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growth factor (IGF) axis plays an important role in 
the development of normal mammary gland where, in 
concert with 17β oestradiol, it regulates the proliferation, 
differentiation and apoptosis of mammary epithelial cells 
during pregnancy, lactation and subsequent involution of 
the gland [2]. It has been suggested that deregulation of the 
IGF axis may be involved in BC initiation, development 
and subsequent metastasis especially with respect to 
underlying tamoxifen resistance. Some studies have 
reported an increased expression of IGF-1R following 
acquisition of TamR [3–6] with the inference that such an 
increase in cell membrane receptor density may lead to an 
increased sensitivity to IGF ligands. In many instances, 
however, such causal relationships have not been validated 
and subsequent studies have reported no alterations or even 
down regulation of IGF-1R expression in TamR cells [7–9]. 
These findings are consistent with the general failure 
of anti-IGF-1R based strategies in clinical trials and have 
led to an interest in the expression and activity of other 
IGF axis components as possible targets in developing 
anti-tumour strategies. Principal amongst these have 
been an examination of IGFBP expression and activity in 
primary BC cells and cell lines. Expression of IGFBPs 
by breast tissue and cell lines is extensively documented 
[10, 11] and they are believed to regulate access of stromal 
derived IGF-1 and -2 to epithelial cell IGF-1R. However 
IGFBPs are also reported to have an IGF enhancing effect 
in breast cancer tissues and also to have direct effects 
that are independent of IGFs [12–14]. These pleiotropic 
actions of IGFBP in breast tissue, and the association of 
the IGF axis with an alternative mitogenic stimulus in 
TamR breast cancer cells, identify IGFBPs as potential 
alternative targets for anti-IGF axis therapeutic strategies. 
Because there is very little data on the expression 
and role of IGFBPs during the acquisition of TamR we 
have examined (i) the expression and activity of IGFBPs 
in the ER+ MCF-7 cell line, (ii) the role of these genes in 
the development of TamR and the migratory phenotype 
and (iii) retrospectively tested whether IGFBPs expression 
and activity was predictive of resistance in a cohort of 
patients with breast cancer and with long term follow up. 
RESULTS
Five of the ten genes of the IGF axis interrogated, 
IGF1R, IGF2R, IGFBP-2, -4 and -5 were expressed at 
moderate to high levels by both wt and TamR MCF- 7 
cells. The other five genes IGF-1, IGF-2, IGFBP-1, 
IGFBP-3 and IGFBP-6 were expressed at very low levels 
– note the logarithmic scale in Figure 1A. Repeated 
qRT-PCR analysis on different batches of cells indicated 
reciprocal regulation of IGFBP-2 and -5 in TamR versus 
wt cells such that IGFBP-2 expression was up regulated 
approximately 10-fold whereas IGFBP-5 expression was 
down regulated approximately 100-fold in TamR cells 
(Figure 1B). Expression of IGF1R, IGF2R or IGFBP-4 
did not significantly differ between TamR and wt cells. 
Changes in IGFBP-2 and -5 mRNA concentrations were 
reflected in protein concentrations in wt and TamR cell 
conditioned medium (CM) as determined by ELISA 
(Figure 2A), Western blot (Figure 2B, upper two panels) or 
IGF ligand blot (Figure 2B, lower panel). Therefore ELISA 
indicated IGFBP-2 concentrations of 1.7 ± 0.69 ng/ ml and 
9.8 ± 0.24 ng/ml (mean ± SD n = 3) for wt and TamR CM 
respectively and IGFBP-5 concentrations of 6.8 ± 0.78 and 
1.4 ± 0.75 ng/ml (mean ± SD, n = 3) both p < 0.0001 wt v 
TamR. These differences were confirmed by densitometric 
analysis of Western blots (Figure 2C). In some instances 
for ligand blot of TamR CM IGFBP-5 was below the 
detection level for this technique – Figure 2 bottom panel 
(lower arrow).
To examine whether differences in IGFBP-2 or 
-5 expression were associated with the development of 
TamR in MCF-7 cells IGFBP-2 was shRNA silenced in 
TamR cells to examine whether this resulted in increased 
sensitivity to 4 HT. Similarly, IGFBP-5 was silenced in wt 
MCF-7 cells to examine whether this induced tamoxifen 
resistance. Scrambled shRNA served as an experimental 
control. Typically, 8–12 clones showed successful 
knock down for IGFBP-2 and IGFBP-5. Figure 3 shows 
IGFBP-2 and IGFBP-5 levels in conditioned medium 
for two stably transfected clones F8 (IGFBP-2) and B4 
(IGFBP-5). Knockdown of over 60% as determined by 
ELISA was achieved in both instances. This established 
these clonal cell lines as appropriate models for 
examination of a causative role for IGFBP-2 and IGFBP-5 
in the development of tamoxifen resistance in MCF-7 
cells. When BP2 silenced and control transfected TamR 
cells were grown in the absence of 4 HT there was little 
difference in the growth curves for the cells with only 
the 96 hr time point showing a statistically significant 
difference (p < 0.05 BP-2 silenced v control-Figure 4A, 
top panel). However, when cells were incubated in the 
presence of 1 µM 4 HT then growth of BP2 silenced 
cells was significantly compromised compared to that of 
control cells at 24, 48 and 72 hr time points (p < 0.001). 
This suggests that knock down of IGFBP-2 expression to 
levels approaching those seen for wt MCF-7 cells partially 
restores sensitivity of cells to 4 HT. For IGFBP-5 knock 
down in wt MCF-7 cells no difference in the growth 
curves for silenced BP5 v control cells was seen in the 
absence of 4 HT (Figure 4B-top panel). However in the 
presence of 1 µM 4 HT the growth of both cell lines was 
inhibited (Figure 4B, bottom panel). This suggests that the 
knock down of IGFBP-5 to levels seen in TamR cells does 
not confer tamoxifen resistance to wt MCF-7 cells. 
The development of TamR in breast cancer 
epithelial cells is often associated with increased cell 
migration. Using IncuCyte real time wound healing 
methodology we confirmed that TamR cells showed more 
rapid migration than wt MCF-7 cells (Supplementary 
Figure S1). Against this background we examined whether 
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sh-BP cell lines had altered migration properties with 
respect to parental wt or TamR cells. For BP2 silenced 
cells migration was significantly lower than that for 
parental TamR cells suggesting that IGFBP-2 knock down 
inhibited cell migration (Figure 5, top panel). However 
there was no significant difference between sh-BP2 and 
sh-control transfected cells with respect to cell migration 
profile suggesting that any effects which were seen were 
non-specific. However for BP5 silenced cells there was 
a specific increase in cell migration evident when using 
Incucyte methodology (Figure 5, bottom panel) suggesting 
that knock down of IGFBP-5 in wt MCF-7 cells 
increased cell migration, resembling the TamR phenotype 
(Supplementary Figure S1) and that IGFBP-5 therefore 
may act as an inhibitor of cell migration.
Because of the association of IGFBP-2 with 
tamoxifen resistance, we next asked whether IGFBP-2 
expression might be a useful marker of tamoxifen resistance 
using a cohort of clinical samples - the relationship between 
IGFBP-2 expression and clinico-pathological parameters is 
shown in Supplementary Table S1(A + B). We used image 
analysis to quantify expression of both of IGFBP-2 staining 
before and after application of the algorithm is shown in 
Figure 6 and described in the accompanying figure legend. 
Kaplan-Meier analysis indicated no significant survival 
differences between IGFBP-2 positive and IGFBP-2 
negative tissues in either the non-stratified cohort or those 
stratified for endocrine sensitivity (cTamR and cTamS; 
Figure 7A–7F). The same analysis was applied to cases 
stained for IGFBP-5; again no statistically significant 
findings were apparent (data not shown).
In silico analysis of data mined from Kaplan Meier 
Plotter in patients who received endocrine treatment showed 
that loss of expression of IGBP-5 at the mRNA level was 
associated with significantly worse overall survival (p = 0.0075; 
HR = 0.3, range 0.11–0.76, Supplementary Figure S2). No such 
relationship was seen with respect to IGBP-2 expression HR 
1.03, range 0.44–2.42. (data not shown). 
Figure 1: (A) Expression of 10 IGF axis genes in MCF-7 cells. Expression is plotted on a logarithmic scale relative to the house 
keeping gene RPLP0 and is represented as 2-ΔCt (see methods section for further details). Moderate to highly expressed genes are indicated 
(*). (B) Expression of IGF1R, IGF2R, IGFBP-2, –4 and –5 in wt and TamR MCF-7 cells. Data is plotted as 2–ΔΔCt and represents the fold 
change in gene expression TamR v wt MCF-7 cells. This experiment was repeated four times with duplicate technical repeats. Data is 
presented as mean ± SD (n = 4).
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DISCUSSION
This work set out to examine the contribution of the 
IGF axis, specifically IGFBP-2 and -5 to the development 
of endocrine resistant breast cancer. We found 5 of the 
10 IGF axis genes were expressed by MCF-7 cells at 
moderate or high levels confirming previous reports 
for this cell line and other ER+ BC cell lines [15, 16]. 
Although 5 of the IGF axis genes are expressed only at 
low levels this does not infer that they play an insignificant 
role in BC [17]. The up regulation of IGFBP-2 following 
the development of TamR in MCF-7 cells has been 
reported previously [18] although siRNA experiments by 
these authors suggested that IGFBP-2 was a marker for 
development of TamR but was not a causative factor in 
this process. This is in contrast to our current observations 
Figure 2: (A) Elisa determination of IGFBP-2 and -5 concentrations in conditioned medium (CM) from wt and TamR MCF-7 
cell lines. Data represent mean ± SD (n = 3). Experiments were repeated on three separate occasions. *p < 0.001, **p < 0.0001 (Student’s 
unpaired t-test). (B) Western blot (upper two panels) and Ligand blot (lower panel) identifies IGFBP-2 (upper arrow Ligand blot) and 
IGFBP-5 (lower panel Ligand blot) in CM from wt and TamR MCF-7 cells. (C) Densitometric analysis of Western blots for IGFBP-2 
(upper graph) and IGFBP-5 (lower graph) band intensity. Triplicate lanes per blot were analysed for both wt and TamR conditioned media 
using Image Lab software. Data are presented as mean +/- SD (n = 3) of Arbitrary Unit (AU) intensity. This experiment was repeated 
3 times with similar results in each instance. *p < 0.005 TamR v MCF-7 Students t-test. GraphPad Prism 5.0.
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where stably transfected IGFBP-2 knock down cells 
clearly exhibited increased sensitivity to 4 HT. These 
differences may be explained by transient transfection 
as opposed to stable transfection protocols used in the 
current study. It is important to note that at later time 
points (96 hr) sensitivity to 4 HT is overcome (Figure 4A 
– lower panel). One explanation for this is that IGFBP-2 
may accumulate both intra- and extracellularly with time 
and reach a threshold value in culture which restores 4 
HT resistance. However this possibility requires rigorous 
investigation. 
IGFBP-5 knock down in wt MCF-7 cells did not result 
in the development of TamR in these cells. Ahn et al. reported 
IGFBP-5 expression decreased in TamR MCF-7 cells 
but also used an RNA screening methodology to indicate 
that IGFBP-5 played a causal role in the determination of 
tamoxifen sensitivity [19]. They also demonstrated that 
shRNA based knockdown of IGFBP-5 expression in MCF- 7 
cells conferred tamoxifen resistance in these cells and 
addition of exogenous IGFBP-5 partly restored sensitivity to 
tamoxifen. Although it is difficult to rationalise our findings 
with those described by Ahn et al. we note that shRNA knock 
down of IGFBP-5 expression led to a loss of ERα expression 
in the studies described by Ahn et al. Similarly Foulstone 
et al. using Western blotting techniques recently demonstrated 
that silencing IGFBP-2 expression ablated ERα expression in 
MCF-7 cells. Although this was not the case in our studies 
where ERα expression was not reduced in TamR BP2 KO 
cells compared to sc transfected cells or untransfected cells 
by qRT-PCR analysis (data not shown) this is an area of 
increasing interest and is worthy of further study. 
The development of TamR is often associated with 
enhanced migration of resistant cells [20]. Although 
we found no specific effect of IGFBP-2 knock down 
on migration of TamR cells there is a literature which 
supports a role for IGFBP-2 in the regulation of MCF- 7 
cell migration and associated phenotypes although it is in 
part conflicted. Therefore, IGFBP-2 has been shown to 
Figure 3: The knockdown of IGFBP-2 expression in TamR cells and IGFBP-5 expression in wt MCF-7 cells. Conditioned 
medium from clone F8 (TamR/BP2 knockdown) and scrambled sequence control transfected TamR cells was assayed for IGFBP-2 by Elisa 
(upper panel). Conditioned medium from clone B4 (wtMCF-7/BP5 knockdown) and scrambled sequence control transfected cells was 
assayed for IGFBP-5 by Elisa (lower panel). Data are expressed as mean ± SD n = 3. Columns with different superscripts are statistically 
different *p < 0.05 Student’s unpaired t-test; GraphPad Prism 5.0.
Oncotarget6www.impactjournals.com/oncotarget
down-regulate PTEN expression by an integrin-mediated 
mechanism in MCF-7 cells culminating in a marked 
increase in cell proliferation [21]. However in MCF-7 
cells over expressing integrin β3, IGFBP-2 inhibits IGF 
mediated cell migration an effect associated with integrin 
mediated localisation of IGFBP-2 to the cell surface 
[22]. An engineered protease resistant IGFBP-2 inhibits 
MCF-7 tumour cell growth as a xenograft in a female 
nude Balb/c mouse model illustrating the importance of 
post-translational modification on the activity of IGFBPs 
[23]. Pleiotropic effects of IGFBP-2 are also evident 
and in the ER -ve Hs578T cell line. IGFBP-2 promoted 
de- adhesion of cells but inhibited proliferation through an 
α5β1 integrin binding mechanism [24]. As this cell line 
lacks a functional IGF1R such effects were postulated 
to occur in an IGF-1 independent fashion and indeed 
subsequent studies using microarray analysis in Hs578T 
cells demonstrated that exogenous IGFBP-2 regulated 
the expression of several genes associated with cell 
proliferation, adhesion and apoptosis [25]. Our data were 
confounded by non-specific inhibition of cell migration in 
sh-con transfected cells arguing for non-specific off target 
effects in respect of this particular phenotype. Alternative 
sh-BP2 targeting vectors and/or sequences may help 
resolve some of the issues highlighted above.
In contrast to the results for IGFBP-2 knock down 
we found clear evidence that knock down of IGFBP-5 
in wt MCF-7 cells was associated with increased cell 
migration and therefore resembled the phenotype of 
TamR cells where IGFBP-5 expression is reduced. These 
data are consistent with previous findings from our group 
which report that IGFBP-5 inhibits MCF-7 cell migration 
[26] and therefore any decrease in IGFBP-5 expression 
may be associated with increased migratory potential. 
IGFBP-5 also enhances adhesion of MCF-7 cells to 
mesenchymal cell derived matrix and may play a role 
in the inhibition of epithelial-mesenchymal transition 
(EMT) a process closely associated with tumour cell 
development and metastasis [27]. In contrast to our data, 
Kricker et al. reported that IGFBP-5 enhanced IGF- 1 
stimulation of MCF-7 cell migration when cultures were 
grown on vitronectin [28] although a distinction must be 
made between IGF-dependant and independent effects 
of IGFBPs. We acknowledge our in vitro data may have 
Figure 4: (A) Growth of TamR BP-2 KO clone F8 or scrambled control cells in the absence (top panel) or presence (bottom 
panel) of 1 uM 4 HT. Cell growth was monitored over the period 0–96 hr. by WST-1 assay as described in Materials and Methods and was 
normalised to t = 0 (100%). This experiment was repeated five times with three technical repeats in each experiment and data is presented 
as mean ± SD (n = 5). In some instances SDs are smaller than the size of the symbol. Curves were analysed by repeated measures ANOVA 
followed by Bonferroni’s post-hoc test *p < 0.05 **p < 0.001 GraphPad Prism 5.0. (B) Growth of WtMCF-7 clone (B4) or scrambled control 
cells in the absence (top panel) or presence (bottom panel) of 1 uM 4 HT. Cell growth was monitored over the period 0–96 hr. by WST-1 assay 
as described in Materials and Methods and was normalised to t = 0 (100%). This experiment was repeated five times with three technical 
repeats in each experiment and data is presented as mean ± SD (n = 5). In some instances SDs are smaller than the size of the symbol. Curves 
were analysed by repeated measures ANOVA followed by Bonferroni’s post-hoc test *p < 0.05 **p < 0.001 GraphPad Prism 5.0.
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Figure 5: Migration of IGFBP knockdown cells plotted as relative wound density (RWD) v time. Top panel – untransfected 
TamR cells (TamR), clone F8 (BP-2 KO) or scrambled shRNA (sc control) transfected cells were seeded and wound closure was measured 
in real time by Incucyte as described in Methods. Bottom panel- untransfected wt MCF-7 cells (wt), clone B4 (BP-5 KO) or scrambled 
shRNA (sc control). Cell migration was monitored over the period 0–96 hr. Data are presented as mean ± SD; n = 12 for each time point. 
This experiment was performed twice with similar results in each instance and a representative experiment is shown. Curves were analysed 
by two way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.0001 BP-5 KO v wt or sc control.
Figure 6: Representative tissue cores showing cytoplasmic staining that represents expression of IGFBP-2 in breast 
cancer. The slides were scanned at x20 magnification using the ScanScope™ system, and visualised for scoring using the ImageScope™ 
pixel intensity Aperio algorithm. Before application of the algorithm, the blue indicates the negative and the brown represents the positive. 
After application of the algorithm, the blue indicates the negative and the red represents the positive. Examples of negative (-), moderately 
positive (+) and strongly positive (++) cores are shown.
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Figure 7: Kaplan-Meier survival curves for both clinically tamoxifen resistant (cTamR) and clinically tamoxifen 
sensitive (cTamS) patients stratified according to IGFBP2 status (A–C) or tamoxifen sensitivity (D–F). Whole cohort 
stratified for IGFBP2 status (a), cTamR (b), cTamS (c), whole cohort stratified for tamoxifen sensitivity (d) cTamR (e), cTamS (f). Data 
were analysed with Univariate Cox regression and p values and Hazard ratios are shown next to relevant panels. 
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limitations as this was generated from a single cell line, 
MCF-7 and its isogenic tamoxifen-resistant variant 
developed in house over 21 months [29, 30]. Nevertheless 
this is consistent with other work in this field where 
MCF- 7 is widely regarded as the most suitable cell line 
to study tamoxifen resistance due to its expression of ERα 
and exquisite hormone sensitivity in vitro [31], with recent 
publications using single MCF-7 derivatives [32, 33].
Our TMA analysis indicated that within both cTamS 
and cTamR cohorts of patients there was no significant 
association between IGFBP-2 (or IGFBP-5) expression 
and overall survival in the relatively modest numbers 
of samples available. Our in silico data mining analysis 
of a smaller, independent data set also failed to show 
a relationship between IGFBP-2 expression and OS. 
Evidence elsewhere for an association between IGFBP-2 
expression and BC progression remains contradictory 
[34] with reports of association and non-association with 
overall survival or tumour progression [35–37]. Other 
studies have suggested that IGFBP-2 (and IGFBP-5) 
expression may provide prognostic or predictive value for 
BC [38], especially with respect to success of endocrine 
therapies [19, 39, 40]. An IHC study on resected BC 
tissues showed a gradual elevation in IGFBP-2 expression 
from atypical hyperplasia through to carcinoma in situ 
and invasive carcinoma [35] and a TMA analysis of more 
than 4,000 primary invasive breast tumours indicated that 
an adverse survival outcome is correlated with IGFBP-2 
expression in ERα negative tumours [41]. IGFBP-2 
expression combined with cell adhesion protein, β-catenin, 
is linked with lymph node metastasis in BCs [42] and high 
levels of IGFBP-2 expression together with loss of PTEN 
expression are also associated with triple negative (TN) 
BC and poor survival rates [43]. IGFBP-2 is up-regulated 
in an in vitro model of Her-2+ BC [44] and recently 
multiple antigenic peptides (MAPs) comprising IGFBP-2 
epitopes have been used to block tumour progression in a 
transgenic mouse model [37, 45]. 
Although no clear relationship between high 
IGFBP-5 expression and overall survival was seen in our 
TMAs from cTamR and cTamS patients (with endocrine 
resistant and endocrine sensitive disease, respectively) 
we did observe a relationship when transcriptomic data 
were assessed using KMPlotter [23]. The reason for this 
apparent discordance is unclear, but there are important 
differences between the analyses. First, the IGFBP-5 
analysis, defined as positive or negative, was conducted 
in patients defined as tamoxifen “sensitive” or “resistant”, 
whereas the in silico was analysis of all patients matching 
the selection criteria with IGFPB-5 expression defined 
as above or below the median. Secondly, there may be 
differences and/or inconsistences in the completeness 
or accuracy of the clinical data between the data sets. 
Finally, whereas in the TMA analysis IGFBP-5 data were 
available for a large proportion of the original population, 
the in silico analysis included only 65 of 3557 patients in 
the KMPlotter database. 
Elsewhere, IGFBP-5 mRNA has been reported to 
be up-regulated in breast tumour tissue relative to normal 
mammary gland although there was no association 
between IGFBP-5 expression and tumour grade [46]. 
Reports suggest that IGFBP-5 is either elevated [47, 48] 
or decreased in lymph node metastases [46] and a high 
IGFBP-5/IGFBP-4mRNA expression ratio is related to 
decreased survival with poor prognosis [48, 49]. However, 
high IGFBP-5 expression has also been associated with 
increased OS [19] and reduced IGFBP-5 protein levels 
have been reported in the stroma surrounding aggressive 
metastatic BC [50]. In this respect it is interesting that 
a recent report demonstrated that co-culture of MCF-7 
with carcinoma associated fibroblasts (CAFs) resulted 
in decreased IGFBP-5 mRNA expression in this BC cell 
line together with development of resistance to the SERD 
fulvestrant [51]. Further experiments with siRNA knock 
down of IGFBP-5 suggested a causal role for IGFBP-5 
in the development of fulvestrant resistance. Whether 
deregulation of IGFBP expression is a causal factor in 
the development of other types of resistance (endocrine, 
chemotherapeutic) is a subject of ongoing investigation in 
our laboratories.
In conclusion, we have found that IGFBP-2 and 
-5 expression are reciprocally regulated following the 
acquisition of TamR in MCF-7 cells in vitro. The co- ordinate 
effects of these IGFBPs on tamoxifen resistance and cell 
migration respectively may provide a mechanism for 
the development of endocrine resistance and subsequent 
metastasis of BC epithelial cells.
MATERIALS AND METHODS
Tissue culture
A TamR derivative of MCF-7 was developed in 
house as previously described [52, 53]. Briefly, cells were 
cultured in phenol-red free RPMI 1640 supplemented 
with 5% dextran charcoal-stripped FCS (Invitrogen)–PR-
DCS, 100 U/ml penicillin and 100 U/ml streptomycin 
and 100 nM 4-hydroxytamoxifen (4-HT; Sigma, Poole, 
UK) for 21-months during which 4-HT resistant variants 
developed. Isogenic controls were cultured in the 
same media, but with ethanol vehicle only. At 70–80% 
confluence cells were passaged (1:4) using 0.25% trypsin-
EDTA (Invitrogen). Cell viability was determined by 
Trypan blue exclusion and cells were seeded at appropriate 
densities as described in the relevant figure legends. Cell 
line provenance was verified by annual STR profiling and 
bi-monthly mycoplasma testing (both in house).
qRT-PCR
RNeasy® Mini Kit (Qiagen, UK) was used to extract 
and purify mRNA exactly according to the manufacturer’s 
protocol. High Capacity RNA to cDNA kit (Applied 
Biosystems, UK) was used according to the manufacturer’s 
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protocol to synthesise single stranded cDNA from 
1 µg mRNA. qRT-PCR reactions were conducted in a 
final volume of 20 µl using TaqMan probes (Applied 
Biosystems). Expression of each gene was analysed in 
triplicate in 96 well plates. Non-template and reverse 
transcriptase negative controls were included. Taqman® 
reactions were amplified using the Roche 480 LightCycler®. 
The amplification protocol included; 2 min at 50°C, 10 min 
at 95°C, and then 40 cycles of 2 step cycling; 15 sec at 
95°C and 1 minute at 60°C. Quantification of PCR data was 
estimated based on the threshold cycle (Ct). RPLP0 was 
used as the housekeeping gene (HKGs) after validation. 
The data were analysed by using the comparative ΔCT 
method (ΔCt (target) – ΔCt HKG) For calculating relative 
changes in gene expression (wt MCF7 v TamR) the ΔΔCt 
method was used where the fold change in gene expression 
is defined as 2–ΔΔCt and is plotted as ordinate.
Western and ligand blot
Conditioned media (CM: 1 ml) were freeze dried 
and stored at –20°C prior to analysis. Anti-hIGFBP‑2 
(MAB6741) and -5 (MAB8751) were from R & D Systems. 
MAB 6741 has < 1% cross reactivity with IGFBP-5; MAB 
8751 has no cross reactivity with IGFBP-2. Anti-β-actin 
was from Santa Cruz Biotechnology. HRP conjugated 
rabbit anti-mouse was from Abcam (ab97046). Western 
blot protocols have been reported previously [54]. Ligand 
blotting with monobiotinylated IGF-2 (AMU010- GroPep) 
and streptavidin-HRP conjugate was as originally described 
[55]. Western and ligand blots were developed with Super-
Signal® West Femto Maximum Sensitivity Substrate 
(PN34095; Fisher Scientific) and images processed using 
Gel-Doc imager (Bio-Rad). 
Enzyme-linked immunosorbent assay (ELISA)
IGFBP-2 and IGFBP-5 concentrations in conditioned 
media were determined by ELISA using IGFBP-2 and 
IGFBP-5 DuoSet ELISA kits (Cat No DY674 and DY578 
- R & D Systems) exactly according to the manufacturer’s 
protocol. Assay range was 62.5–4000 pg/ml (IGFBP-2) 
and 125–8000 pg/ml (IGFBP-5). CM samples were diluted 
appropriately to fall within this range.
IGFBP knockdown 
A shRNA based strategy was used to knock down 
IGFBP-2 and IGFBP-5 expression in TamR and wt MCF-7 
cells respectively. IGFBP-5 shRNA plasmid (sc-39591-sh), 
IGFBP-5 shRNA plasmid control (sc-108060), IGFBP-2 
shRNA plasmid (sc-37195-sh), IGFBP-2 shRNA plasmid 
control (sc-108060) puromycin (CAY13884-25), shRNA 
plasmid transfection medium (sc-108062) and transfection 
reagent (sc-108061) (all Santa Cruz Biotechnology Inc., 
UK). Cells were transfected essentially according to the 
manufacturer’s protocol. Briefly, cells (5 × 105) were 
incubated in 6 well plates in PR-DCS at 37°C until 50–70% 
confluent. Cells were washed with 1 ml transfection media 
and incubated with 1 µg IGFBP or control shRNA plasmids 
and 0.5– 3% (v/v) transfection reagent in a final volume of 
1ml for 6 hr. After a further 6 hr, 1 ml of PR- 10% DCS was 
added to each well and incubation continued overnight. 
Stable transfectants were selected in PR-DCS containing 
6 μg/ µl puromycin with media changes every 3–5 days. 
Puromycin resistant cells grew through at 3–4 weeks. 
Heterogeneous cell populations were expanded and after 
assay for IGFBP-2 and IGFBP-5 by ELISA cells were cloned 
by limiting dilution. After 2 weeks individual colonies were 
identifiable in a significant proportion of microtitre wells. 
Typically 6 such clones were allowed to grow to confluence 
and medium collected for IGFBP-2 or IGFBP-5 assay by 
ELISA. IGFBP concentrations in CM were compared to 
those obtained in contemporaneously grown wtMCF-7 and 
TamR cells and scrambled control shRNA clones. Clones 
which showed the highest level of knock down were 
subsequently expanded and stored as frozen stocks.
Cell proliferation 
Wt MCF-7, TamR, IGFBP-2 and IGFBP-5 
knockdown or scrambled control shRNA clones were seeded 
in PR-DCS in 96 well plates at 5 × 103 cells per well (100 µl 
suspension). After attachment overnight cells were washed 
with PBS and growth was monitored over the period 0–96 hr 
in PR-DCS ± 1 uM 4-hydroxy tamoxifen (4 HT). 
Incucyte cell migration assay
Cells were seeded in 96-well Essen Image Lock plates 
at 5 × 105 per well in PR-DCS. Plates were incubated for 18 h 
to allow cell attachment following which sterilised 96-well 
Wound-Maker pins were used to simultaneously generate 
precise and reproducible cell-free zones 700–800 µm wide in 
cell monolayers. Plates were placed in the IncuCyte incubator 
at 37°C and equilibrated for a minimum of 15 minutes before 
the first scan. IncuCyte software acquires images in real time 
at 1 hr intervals for the duration of the experiment (96 h) and 
integrated software quantifies cell migration using the metric 
relative wound density (RWD). Migration of six different cell 
lines was analysed using this technique – parental wt and 
TamR MCF-7 cells; IGFBP-2 KO (clone F8) and scrambled 
shRNA control; IGFBP-5 KO (clone B4) and scrambled 
shRNA control. Data are presented along as plots of RWD 
v time. For each cell line 12 replicates were performed and 
data are generated as mean ± SD.
Immunohistochemistry 
Tissue microarray (TMA) construction and 
immunohistochemistry
Ethical approval was obtained from the Leeds 
(East) Local Research Ethics Committee at St James’s 
University Hospital, Leeds, UK (06/Q1206/180). TMAs 
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were constructed previously from an initial series of 
351 cases of primary operable invasive breast carcinoma 
from patients presenting from 1987–2005 all of whom 
had received TAM and comprised, initially, 108 and 
243 cases who did or did not experience a relapse, 
respectively [56]. As this series has been used extensively 
in other publications [57–60] some of the TMA cores 
were exhausted, meaning that in this study 77 relapsed 
and were designated clinically TamR (cTamR) while 
193 did not relapse and were designated clinically TamS 
(cTamS) were available for study. Mean follow up time 
for the former was 87 months (range 11–199) and the 
latter 101 months (range 7–214). Survival in the cTamR 
cohort was updated in June 2015 and the cTamS cohort in 
July 2013. The TamS cohort were updated 2 years earlier 
than the resistant patients and some may have relapsed 
in the subsequent 2 years however as indicated above the 
median follow up was actually longer for the TamS cohort 
than the TamR cohort (101 and 87 months, respectively). 
Patients were censored at the last day they were known 
to be alive. Histopathological details are presented in 
Supplementary Table S1A and S1B. The cTAMs patients 
had lower grade, smaller tumours and a higher proportion 
of IGFBP-2 positive tumours (Supplementary Table S1A). 
The IGFBP-2 positive tumours were smaller than the 
IGFBP-2 negative tumours (Supplementary Table S1B).
Using the Human Protein Atlas (http://www.
proteinatlas.org/), suitable IGFBP-2 and IGFBP-5 
antibodies were identified (Abcam-ab109284; and Santa 
Cruz SC-6006) respectively. These antibodies do not 
cross react with the other IGFBPs. Negative controls 
(primary antibody omitted) were also included. Antigen 
retrieval was achieved after de-waxing using Mena Path 
Revelation buffer solution (cat no MP-607-X500) in the 
Mena Path pressure cooker containing 500 ml distilled 
water for 40 minutes. Immediately following this slides 
were immersed in PBST (1× TBS containing 0.2% Tween 
20) buffer then distilled water. Then, slides were washed 
in PBST and blocked with 100 μl Novacastra peroxidase 
(cat no RE7101) for 10 minutes, washed with PBST, then 
100 μl of protein blocking solution (cat no RE7102) was 
added and incubated for 2 minutes (both incubations 
at room temperature). Rabbit monoclonal antibodies 
against hIGFBP-2 (1:50 v/v) and goat polyclonal 
antibody against IGFBP-5 (1:50 v/v) were added and 
incubated at room temperature for 1 hour. Slides were 
washed 3 times for 5 minutes with PBST and 100 μl of 
secondary antibody (Novolink polymer cat no RE7112) 
was added and incubated for 30 minutes. After washing 
3 times in PBST for 5 minutes 100 μl of the diluted DAB 
chromogen (1:20 v/v ;) cat no RE7105) was added to each 
slide and incubated at room temperature RT (5 minutes). 
Rehydration was achieved through graded alcohols, 100%, 
75%, 50%, and 25% f (3 minutes in each), and washed 
in running tap water. Endogenous peroxidase activity 
was blocked (0.75% H2O2, 20 minutes) and then rinsed 
in running tap water. Slides were counter stained by 
immersing in Mayer’s haematoxylin for 1 minute, washed 
in running tap water, then immersed in Scott’s tap water 
for 2 minutes followed by a further wash in running tap 
water. The slides were then dehydrated in a series of 
ethanols (25% for 15 seconds, 50% for 2 minutes, 70% 
for 5 minutes, and 100% for 5 minutes) then immersed 
in xylene 3 times for 3 minutes. [65] Finally, slides were 
mounted in DPX and cover-slips applied. Subsequently, 
slides were scanned (Aperio ScanScope®) and scored using 
a pixel intensity algorithm (Aperio) A Receiver Operating 
Characteristic Curve (ROC) was used to determine the 
optimal cut-off point using an online program (http://
molpath.charite.de/cutoff/; [61]. 
In silico analysis
An online survival analysis tool was used to 
study the relationship between IGFBP-5 and IGFBP-2 
expression and overall survival (Kaplan Meir Plotter; 
http://kmplot.com/analysis/ (accessed 9 Nov 2015). This 
data set comprises 3557 patients with overall survival 
data on 1117 patients As the focus had been on tamoxifen 
sensitivity and resistance, we selected a cohort of 65 
patients with IGFBP-5 and IGFBP-2 expression data 
(classified as either above or below the median) who had 
received tamoxifen therapy, irrespective of ER status and 
whether they received chemotherapy.
Statistics
Data were analysed for significant differences 
using Student’s unpaired t-test (ELISA) or repeated 
measures ANOVA followed by Bonferroni’s post-hoc 
test. Fisher’s exact test was performed to demonstrate 
relationships between immunohistochemical findings 
and clinicopathological variables. Survival durations 
in months were calculated using Statistical Package for 
Social Sciences (SPSS) version 22 software and Log-rank 
test (Mantel–Cox test) test was used to plot Kaplan-Meier 
survival curves. 
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